| First Author | Elayeb R | Year | 2017 |
| Journal | J Immunol | Volume | 199 |
| Issue | 11 | Pages | 3771-3780 |
| PubMed ID | 29055003 | Mgi Jnum | J:256362 |
| Mgi Id | MGI:6105722 | Doi | 10.4049/jimmunol.1700754 |
| Citation | Elayeb R, et al. (2017) Anti-CD20 Antibody Prevents Red Blood Cell Alloimmunization in a Mouse Model. J Immunol 199(11):3771-3780 |
| abstractText | Alloimmunization against RBCs can cause life-threatening delayed hemolytic transfusion reactions. Anti-CD20 Ab has recently been used to prevent alloimmunization. However, its effects remain unclear, particularly in lymphoid organs. We investigated the impact of murine anti-CD20 Ab in the blood and spleen. We assessed protocols for preventing primary alloimmunization and for abolishing established alloimmunization. Prophylactic protocols prevented alloimmunization. However, anti-CD20 treatment could only limit the further amplification of established alloimmunization. Residual B cell subtype distribution was disrupted in the spleen, but adoptive transfer studies indicated that these cells were neither plasma nor memory cells. Anti-CD20 Ab had a major effect on alloreactive CD4(+) T cells, increasing the expansion of this population and its CD40 expression, while lowering its CD134 expression, thereby confirming its role in alloimmunization. In conclusion, this study shows that anti-CD20 immunotherapy can prevent RBC Ab development. However, this immunotherapy is limited by the increase in alloreactive CD4(+) T lymphocytes. Nevertheless, treatment with anti-CD20 Abs should be considered for patients requiring transfusion with a very high risk of alloimmunization and life-threatening complications. |
